Skip to main content
Home
About Us
About Compugen
Leadership
Board of Directors
Scientific and Strategic Advisory Board
Contact Us
Our Science
Unigen™
Pipeline
Clinical Trials
Publications
Investors and Media
Overview
Press Releases
Events
Stock Information
NASDAQ: CGEN
TASE: CGEN.TA
Analyst Coverage
Financials
Quarterly Results, Annual Reports and Proxy
SEC Filings
Media
Governance
Governance Documents
Leadership
Committee Composition
Investor Contacts
Investor FAQs
Corporate Presentation
Collaborations
Careers
Follow Us
LinkedIn
X
Email Alerts
News Details
View All News
Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA
December 1, 2022
Abstract 420
(opens in new window)
Moroney J et al, ESMO-IO 2022
View All News